Simultaneous Detection of Infectious Diseases Using Aptamer-Conjugated Gold Nanoparticles in the Lateral Flow Immunoassay-Based Signal Amplification Platform

Various platforms for the accurate diagnosis of infectious diseases have been studied because of the emergence of coronavirus disease (COVID-19) in 2019. Recently, it has become difficult to distinguish viruses with similar symptoms due to the continuous mutation of viruses, and there is an increasi...

Full description

Saved in:
Bibliographic Details
Published in:Analytical chemistry (Washington) 2024-01, Vol.96 (4), p.1725-1732
Main Authors: Kim, Jinwoo, Baek, Sowon, Nam, Jungmin, Park, Jeongeun, Kim, Kihyeun, Kang, Juyoung, Yeom, Gyuho
Format: Article
Language:English
Subjects:
Amplification
Antigens
Aptamers
Coronaviruses
COVID-19
Cross-reactivity
Diagnosis
Gold
Immunoassay
Infectious diseases
Influenza
Influenza A
Influenza B
Nanoparticles
Signs and symptoms
Viral diseases
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Various platforms for the accurate diagnosis of infectious diseases have been studied because of the emergence of coronavirus disease (COVID-19) in 2019. Recently, it has become difficult to distinguish viruses with similar symptoms due to the continuous mutation of viruses, and there is an increasing need for a diagnostic method to detect them simultaneously. Therefore, we developed a paper-based rapid antigen diagnostic test using DNA aptamers for the simultaneous detection of influenza A, influenza B, and COVID-19. Aptamers specific for each target viral antigen were selected and attached to AuNPs for application in a rapid antigen diagnosis kit using our company’s heterogeneous sandwich-type aptamer screening method (H-SELEX). We confirmed that the three viruses could be detected on the same membrane without cross-reactivity based on the high stability, specificity, and binding affinity of the selected aptamers. Further, the limit of detection was 2.89 pg·mL–1 when applied to develop signal amplification technology; each virus antigen was detected successfully in diluted nasopharyngeal samples. We believe that the developed simultaneous diagnostic kit, based on such high accuracy, can distinguish various infectious diseases, thereby increasing the therapeutic effect and contributing to the clinical field.
ISSN:0003-2700
1520-6882
DOI:10.1021/acs.analchem.3c04870